Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Metrics to compare | ESPR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipESPRPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.0x | −0.8x | −0.6x | |
PEG Ratio | −0.07 | −0.01 | 0.00 | |
Price/Book | −1.2x | −0.1x | 2.6x | |
Price / LTM Sales | 1.5x | 4.4x | 3.1x | |
Upside (Analyst Target) | 194.1% | 208.9% | 53.6% | |
Fair Value Upside | Unlock | 1.7% | 8.0% | Unlock |